Michael Steinberg, Chair of the Department of Radiation Oncology in the David Geffen School of Medicine at UCLA, shared on X:
“New research led by Dr. Amar Kishan shows combining PSMA-targeted radioligand therapy with SBRT reduces recurrent prostate cancer progression risk by 62%.
By targeting visible tumors and microscopic cells, it delays the need for hormone therapy.”
You can also read :
FDA Fast Track Designation: BiPASS for Pre-Biopsy PSMA-PET Imaging in Prostate Cancer
